Andere Sprachen Formycon AG

Aktien

A1EWVY

DE000A1EWVY8

FYB

Markt geschlossen - Xetra Andere Börsenplätze 17:36:17 18.04.2024			% 5 Tage	% 1. Jan.
39,7 ^EUR	-1,24 %		-14,16 %	-29,61 %

15.04.	MORNING BRIEFING - Deutschland/Europa	DJ
12.04.	NACHBÖRSE/XDAX -0,4% auf 17.863 Pkt - Formycon nach Zahlenausweis gesucht	DJ

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast	12.04.
Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year	12.04.
Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)	11.04.
Fresenius Kabi And Formycon Reach Settlement Agreement For Ustekinumab Biosimilar Candidate In Europe And Canada	03.04.
Updates On Aflibercept BPCIA Litigation	26.03.
Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar	18.03.
Fresenius Settles With Johnson & Johnson to Market Stelara Alternative	18.03.
Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada	18.03.
Formycon Wins Regulatory Nod for Lucentis Biosimilar in Saudi Arabia	11.03.
FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region	11.03.
Updates On Aflibercept BPCIA Litigation	19.02.
AVIS D'ANALYSTES DU JOUR : Danone, Carrefour, Michelin, Hermès, Air France, Rémy Cointreau, Soitec, X-Fab...	13.02.
OPINIONES DE LOS ANALISTAS DEL DÍA : BBVA, Rovi, Bankinter, Banco Santander, Hermès, Inditex, Iberdrola, Fagron, X-Fab...	13.02.
Formycon Sells 9% Interest to Gedeon Richter for EUR83 Million	30.01.
Gedeon Richter becomes strategic investor of Formycon via equity investment	29.01.
Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor	29.01.
Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023	18.01.
Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation	11.01.
Formycon to present at the 42nd Annual J.P. Morgan Healthcare Conference	04.01.
Deutsche Borse to publish cash market annual statistics 2023	03.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Formycon AG: Wachstum trotz starker Konkurrenz im Biosimilar-Markt

Am 19. September 2023 um 20:19 Uhr